Other clinical trials to assess the use of everolimus or other mTOR inhibitors (ridaforolimus, temsirolimus, or TAK-228) have been carried out but center on HER2 metastatic BC resistant to trastuzumab (e.g., NCT01783756 [139], NCT00736970 [140], and NCT01111825). This evidence concerns the gene ERBB2 and breast cancer.